Frank Cortazar, MD
Nephrology · Albany, NYNPI 1699060368
Payments from drug & device makers
Across 313 payments — averaging $3620.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$497K
- Novartis$335K
- Vertex$194K
- Travere Therapeutics, Inc.$49K
- Calliditas Therapeutics US Inc.$31K
- Aurinia Pharma U.S., Inc.$21K
- plus $6K from 16 others
Across 2 payments — averaging $4086.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$8K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 140 | $496,706 |
| Novartis | 23 | $335,040 |
| Vertex | 4 | $194,478 |
| Travere Therapeutics, Inc. | 22 | $49,162 |
| Calliditas Therapeutics US Inc. | 44 | $30,870 |
| Aurinia Pharma U.S., Inc. | 21 | $20,815 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $3,679 |
| AstraZeneca(2 entities) | 14 | $1,383 |
| GSK | 12 | $218 |
| Mallinckrodt Hospital Products Inc. | 6 | $153 |
| Otsuka America Pharmaceutical, Inc. | 5 | $127 |
| Ardelyx, Inc. | 1 | $123 |
| Bayer | 3 | $80 |
| Boehringer Ingelheim | 3 | $71 |
| Alnylam Pharmaceuticals Inc. | 3 | $62 |
| Genentech USA, Inc. | 2 | $42 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $14 |
How this compares
$1,133,131 in reported general payments places this provider in the 95th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Albany
- Vincent CarsilloAlbany$191K
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
- Andrew BombackNew York$3.4M
- Pietro CanettaNew York$3.2M
- Robert LynnBronx$2M
- Jodumutt BhatMaspeth$1.5M
- Gerald AppelNew York$1.5M
- David CharytanNew York$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.